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Background: This study aims to determine the incidence of pulmonary embolism (PE) in trauma and orthopedic
patients within a regional tertiary referral center and its association with the pattern of injury, type of treatment,
co-morbidities, thromboprophylaxis and mortality.
Methods: All patients admitted to our institution between January 2010 and December 2011, for acute trauma or
elective orthopedic procedures, were eligible to participate in this study. Our cohort was formed by identifying all
patients with clinical features of PE who underwent Computed Tomography-Pulmonary Angiogram (CT-PA) to
confirm or exclude the clinical suspicion of PE, within six months after the injury or the surgical procedure.
Case notes and electronic databases were reviewed retrospectively to identify each patient’s venous
thromboembolism (VTE) risk factors, type of treatment, thromboprophylaxis and mortality.
Results: Out of 18,151 patients admitted during the study period only 85 (0.47%) patients developed PE (positive
CT-PA) (24 underwent elective surgery and 61 sustained acute trauma). Of these, only 76% of the patients received
thromboprophylaxis. Hypertension, obesity and cardiovascular disease were the most commonly identifiable risk
factors. In 39% of the cases, PE was diagnosed during the in-hospital stay. The median time of PE diagnosis, from
the date of injury or the surgical intervention was 23 days (range 1 to 312). The overall mortality rate was 0.07%
(13/18,151), but for those who developed PE it was 15.29% (13/85). Concomitant deep venous thrombosis (DVT)
was identified in 33.3% of patients. The presence of two or more co-morbidities was significantly associated with
the incidence of mortality (unadjusted odds ratio (OR) = 3.52, 95% confidence interval (CI) (1.34, 18.99), P = 0.034).
Although there was also a similar clinical effect size for polytrauma injury on mortality (unadjusted OR = 1.90 (0.38,
9.54), P = 0.218), evidence was not statistically significant for this factor.
Conclusions: The incidence of VTE was comparable to previously reported rates, whereas the mortality rate was
lower. Our local protocols that comply with the National Institute for Health and Clinical Excellence (NICE)
guidelines in the UK appear to be effective in preventing VTE and reducing mortality in trauma and orthopedic
patients.
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Pulmonary embolism (PE) and deep venous thrombosis
(DVT) can be considered under the spectrum of venous
thromboembolic (VTE) disease. No definitive scientific data
exist regarding the overall incidence of VTE in the general
population, but a recent study estimates the incidence to
range between 1 and 5/1,000 in the general population [1].
In the surgical population, the prevalence can reach more
than 50% in the absence of thromboprophylaxis [1].
Worldwide, more than 50% of all hospitalized patients
are at risk for VTE and surgical patients are at higher
risk than medical patients [2]. The incidence of PE rep-
resents 5 to 10% of deaths in the hospital setting, mak-
ing this condition the most common preventable cause
of in-hospital death [3-6]. In addition, VTE and asso-
ciated complications contribute substantially to patient
morbidity and treatment costs [7,8].
Within the discipline of trauma and orthopedics, the
prevalence of DVT and PE has been estimated to be
1.16% and 0.93%, respectively [9]. Mortality rates have
been reported to range between 0.38% and 13.8% [10,11].
Principal risk factors include an injury severity score
(ISS) greater than 50 and more than two surgical proce-
dures [9]. PE appears to be the most common cause of
mortality in patients that survive the first 24 hours fol-
lowing trauma and retrospective post-mortem data have
demonstrated that out of an overall mortality of 13.8%,
1.6% was a consequence of fatal PE [10]. In the elective
orthopedic clinical setting, PE is the second most fre-
quent cause of death in patients that undergo lower limb
total joint arthroplasty [11].
Despite the existing data reporting on the overall pre-
valence of PE in the trauma and orthopedic population,
it remains a common belief that as the clinical signs and
symptoms are non-specific and frequently silent, this
complication may still be underdiagnosed [12]. The aim
of this study is to determine the incidence of PE in
trauma and orthopedic patients admitted to one of
the largest tertiary referral centers in the UK and to
investigate its association with the pattern of injury,
type of treatment, co-morbidities, thromboprophylaxis
and mortality.
Methods
Study design and setting, and study population
This cohort study was performed in a single center (a
large UK teaching hospital - NHS trust). All patients
admitted to our institution, from January 2010 to De-
cember 2011, for acute trauma or elective orthopedic
procedures were eligible to participate in this study. Pa-
tients admitted for medical reasons or for other surgical
causes not relevant to our discipline were excluded.
The study group of patients was formed by selecting
all the patients who had clinical features suggestive ofPE and who underwent subsequent radiological investi-
gation (Computed Tomography Pulmonary Angiogram,
CT-PA) to either confirm or exclude the clinical suspi-
cion, within six months after the index orthopedic or
acute trauma procedure. All patients gave written in-
formed consent.
In our hospital, we use multidetector CT scanners (16-
and 64-detector row). Higher specification machines are
available, namely 128 and 320 slice, but the standard
technique is similar. The main contraindications are re-
nal failure and iodine allergy. In these cases a ventila-
tion/perfusion (V/Q) scan is performed to confirm the
diagnosis of pulmonary embolism. When an acute life
threatening PE is suspected, a bedside echo looking for a
right heart strain is also used. Further available options
include pulmonary angiography and gadolinium enhanced
MRI, but these are rarely performed or used due to their
invasive nature and logistic difficulties.
CT-PA scans were considered as positive according to
the following criteria: failure of contrast material to fill
the entire lumen because of a central filling defect (the
artery may be enlarged, as compared with similar ar-
teries); a partial filling defect surrounded by contrast
material on a cross-sectional image; contrast material
between the central filling defect and the artery wall on
an in-plane, longitudinal image; and a peripheral intra-
luminal filling defect that forms an acute angle with the
artery wall [13,14]. A CT Venogram (CTV) was rou-
tinely performed in those patients that had a positive
CT-PA.
PE is usually classified as proximal or distal depending
on the location of the emboli identified on the CT scan.
Usually when the emboli are located within the main or
lobar arteries they have been reported as proximal PE
and anything segmental or sub-segmental is usually re-
ported as distal PE [15].
Institutional Board Review approval (Leeds Teaching
Hospital NHS Trust) was obtained for this study (IBR
number 10138).
Data collection
Health records and electronic databases were further
reviewed to identify a patient’s risk factors for developing
VTE disease (according to the guidelines produced by
NICE (National Institute for Health and Clinical Excel-
lence httreatmentprotocol://guidance.Nice.org.uk/CG92;
httreatmentprotocol://guidance. nice. Org.uk/CG46) [16].
Patient co-morbidities, the length of in-hospital stay,
the characteristics of orthopedic interventions, the use
of thromboprophylaxis (TP), the timing of PE diagno-
sis from the time of admission, as well as mortality,
were all recorded. The severity of the PE episode was
evaluated using the simplified Pulmonary Embolism
Severity Index [17].
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All patients admitted to our institution, are expected to
receive an initial risk assessment for VTE and have a
specific form completed to identify risk factors, accord-
ing to the current standard operating procedure of the
Trust. This assessment tool has been developed in line
with NICE guidelines [16]. This evaluation allows pre-
scription of the most suitable mechanical and/or pharma-
cological TP treatment. This risk assessment is completed
on admission and is reassessed during inpatient stay and
adjusted according to the patient’s clinical condition. All
patients are given a leaflet relevant to VTE and the mea-
sures that should be taken to minimize the risk of deve-
loping PE.
Patients undergoing elective total hip and knee arthro-
plasty surgery (THA, TKA) are treated with mechanical
VTE prophylaxis (mechanical TP treatment), (anti-em-
bolism stockings/alternative pneumatic devices from ad-
mission). Chemical thromboprophylaxis (chemical TP),
with low-molecular weight heparin (LMWH) is provided
post-operatively once the risk of bleeding is reduced (the
wound is dry or the hemoglobin fall is <2 g/dl). Che-
mical TP treatment is continued for 35 days in patients
undergoing THA, and 14 days for TKA [18-20]. With
reference to other orthopedic procedures, including up-
per limb surgery, a TP treatment is not routinely pre-
scribed, unless the patient is at risk of developing DVT/
PE as highlighted in our risk assessment questionnaire
tool. In these cases the patient is informed and applica-
tion of mechanical VTE prophylaxis is considered. Ad-
ministration of LMWH, 6 to 12 hours after surgery, is
also considered. The administration of the mechanical
VTE prophylaxis and LMWH is continued until the pa-
tient is fully mobile.
The TP treatment used for hip fractures is similarly
based on patient risk assessment and starts with mech-
anical TP treatment. LMWH is administered once per
day (usually tinzaparin 4,500 IU or enoxaparin 20 mg in
patients with renal failure). Chemical TP treatment is in-
terrupted 12 hours before surgery but restarts when the
risk of bleeding is reduced and is continued for 28 days.
Mechanical TP treatment is continued until the patient
is fully ambulant [21].
Patients with major trauma or spinal injury routinely
receive a mechanical TP treatment on admission. The
risk of VTE and bleeding are also evaluated to determine
the timing of initiation of a chemical TP treatment. The
TP treatment is continued until mobility is fully restored
(usually eight weeks for patients with pelvic and acetab-
ular fractures). In cases where the risks of both VTE and
bleeding are high and there is a previous positive PE his-
tory, a vena cava filter is inserted [22].
The use of lower limb plaster casts increases a pa-
tient’s risk for VTE. The patient is informed and asubsequent risk assessment is performed. LMWH treat-
ment (tinzaparin 4,500 units or enoxaparin 20 mg in pa-
tients with renal failure) is prescribed for the whole time
period of immobilization [23].
As a general measure, we recommend that all patients
should, where possible, undergo early mobilization and
regular exercises to minimize the risk of VTE.
Statistical analysis
Continuous variables were summarized in terms of mean
values with standard deviation and range as measures of
variability. For variables that have skewed distributions, or
otherwise may not be well represented by a normal distri-
bution, medians and inter-quartile range are reported ra-
ther than mean and standard deviation. Categorical values
were presented as absolute frequencies and percentages.
Data were processed and analyzed by MedCalc version
12.2.1 (MedCalc software bvda, Mariakerke, Belgium).
Mortality following PE was modelled using a multivar-
iable logistic regression on potential risk factors. These
were assessed using a Wald test with a P-value of 0.05
or less considered to be statistically significant. Model-
ling was undertaken using the software development
environment R version 3.0.0 [24]. It is noted that the
analysis is exploratory only, to identify those factors
most strongly associated with mortality. A variety of
plausible models, including and excluding covariates,
were explored and the final model presented is a par-
simonious one, which includes only statistically sig-
nificant predictors.
Results
Over the pre-specified study period, 18,151 orthopedic
patients (10,648 for elective operations and 7,503 for
trauma) were admitted to our institution. During the
same study period, 5,656 CT-PA investigations were re-
quested by all the medical disciplines out of which 151
(2.67%) requests were from the discipline of trauma and
orthopedics. Six hundred and fifty (11.5%) patients had
positive findings of PE. Out of the positive 650 cases, 86
(13.2%) patients were from our discipline (trauma and
orthopedics) and formed the study cohort. Taking into
consideration the number of clinically suspected PE (151)
and the number of positive findings on the CT-PA (86 pa-
tients) it was estimated that 57% of patients presenting
with clinical features consistent for PE had positive radio-
logical CT-PA findings. One patient, however, was ex-
cluded from the study as the PE event occurred shortly
prior to hospital admission for TKA and, thus, 85 patients
formed the study cohort (see Figure 1).
Characteristics of the population
The mean age of patients was 66.3 years (range 18 to
98 years) and there was an almost equal gender
5,656 patients with clinical 
features of PE from all the 
medical disciplines
151 (2.67%) from the    




650 (11.5%) patients with 
positive findings of PE
86 patients from the 
discipline of trauma and 
orthopedics
85 patients forming the study group
(1 patient excluded—PE event prior the 
hospital admission)
Figure 1 Data flow for patients included in the study group.
Gudipati et al. BMC Medicine 2014, 12:39 Page 4 of 11
http://www.biomedcentral.com/1741-7015/12/39distribution (M:F = 42:43). Dividing the age of patients
into decades, the most populated categories were 50 to
59 years (16.5%), 60 to 69 years (17.6%), 70 to 79 years
(24.7%), 80 to 89 years (15.3%) (Figure 2).
Type of injuries and surgical procedures
Out of the 85 patients, 24 (28.2%) underwent elective
orthopedic procedures with the most frequent being
THA and TKA. Less common procedures included knee
arthroscopy and spinal surgery. Sixty-one patients were
admitted following trauma. Of these 61 patients with







18 to 29 30 to 39 40 to 49 50 to 59 60 to 69 70 to 79 80 to 89 90 to 99
Males Females
Figure 2 Age range and gender distribution vs number of
patients (that is, frequency).injuries. The vast majority of the injured patients sus-
tained lower limb trauma (Tables 1 and 2).
Co-morbidities and risk factors for VTE
Most of the patients had multiple comorbidities/risk fac-
tors. Because of the presence of more than one risk fac-
tor in each patient, the overall combination is more than
100%. More than four co-morbidities were present in 8
patients (9.4%), three in 20 patients (23.5%) and two in
26 patients (30.6%). The prevalence of known common
risk factors for VTE and co-morbidities in the study co-
hort were: hypertension (36.8%), obesity (35.5%), cardiac
disease (31.6%) and vascular disease (23.7%). The mean
Charlson Co-morbidity Index was 1.7 (range: 0 to 10)
and was greater or equal to 3 in 23 (30.26% of) patients
(Table 3).
Thromboprophylaxis
Thromboprophylaxis was prescribed and administered
in 65 cases (76.5%), representing the “prescribed TP”
group. Aspirin alone was administered in six patients,
which was not considered as an appropriate thrombo-
prophylactic agent; thus, these cases were included to
the “non-prescribed TP” group for all subsequent ana-
lysis. LMWH was used in the majority of cases (69.4%)
(Table 4).
Within the 65 patients receiving TP, 4 (4.7%) received
mechanical TP only (two of these patients underwent
TKA and developed above knee DVT). In two cases
(2.4%) an inferior vena cava filter was inserted for
Table 1 Frequency, mortality and time of death
Elective
Type of procedure or injury Number of patients % Mortality (N),% Time to death after PE diagnosis
Total hip arthroplasty 6 7% 0
Total knee arthroplasty 10 11.8% 0
Spine 3 3.5% (2) 2.4% 112
Knee arthroscopy 3 3.5% 0
Femoral osteotomy 1 1.2% 0
Metalwork removal 1 1.2% 0
Sum 24 28.2% (2) 2.4% Median: 112
Trauma
Type of procedure or injury Number of patients % Mortality (N),% Time of death after PE
Femoral neck fixation 9 10.6% (4) 4.7% 36 (5.9%) 21 days
Hemiarthroplasty 5 5.9% (1) 1.2% 6
Other lower limb injury 35 41.2% (4) 4.7% 21
Upper limb injury 9 10.5% (2) 2.4% 134.5
Pelvis and acetabulum 2 2.4% 0
Vertebral fracture 1 1.2% 0
Sum 61 71.8% (11) 12.9% Median: 36
Entire PE cohort 85 100% (13) 15.3% Median: 69
The time elapsed between the episode of PE and the death of patients, expressed in days, are also shown. PE, pulmonary embolism.
Table 3 Distribution of co-morbidities and VTE risk factors
Risk factor Pat. N. %
Malignancy 12 14.1%
Previous VTE 10 11.8%
Diabetes 10 11.8%
Chronic obstructive
Pulmonary disease 13 15.3%
Cardiac disease 24 28.2%
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left in situ permanently.
Out of the 20 cases that did not receive TP, 7 (8.2%)
patients did not have TP prescribed on account of un-
dergoing a minor orthopedic procedure (three patients
underwent knee arthroscopy, four patients sustained up-
per limb injuries (radial head fracture, rotator cuff tear,
wrist and clavicle fracture). Out of the remaining 13
(15.3%) trauma patients, 11 patients did not receive TP
(incomplete evaluation of patient risk profile and partial
ambulation of patient), whereas 2 patients refused treat-
ment. Two patients from the trauma group were treatedTable 2 Lower limb injuries details: type of injury and
relative mortality
Type of lower limb injuries Pat. N Death
Femoral neck death 5 (5.9%)
Femoral diaphyseal fracture 2 0
Distal femur fracture 3 0
Tibial plateau fracture 9 (1) 1.2%
Tibial diaphyseal fracture 1 0
Ankle fracture 11 (1) 1.2%
Foot fracture death 2 (2.4%)
Multiple lower limb
Fractures 5 0
Total meath 9 (10.7%)
Pat. N, number of patients.
Obesity 27 31.8%
Hypertension 28 32.9%
Vascular disease 18 21.2%
Thrombophylic disorders 1 1.2%
Contraceptives 3 3.5%
Hormonal therapy 4 4.7%
Varicose veins 2 2.4%
Rheumatic disease 5 5.9%
More than two comorbidities 26 30.6%
More than three comorbidities 20 23.5%
More than four comorbidities 8 9.4%
Median Range
Charlson Comorbidity Index 2 IQR = 0 to 3 0 to 10
Pat. N, number of patients; VTE, venous thromboembolism.
%, prevalence of the co-morbidity in the cohort.
Charlson Co-morbidity index is also shown.
Table 4 Characteristic of thromboprophylaxis
Treatment protocol yes Pat. N. %
Number of patients 65 76.5%
Type of TP treatment:
LMWH 59 69.4%
Mechanical TP 4 4.7%
ICF 2 2.4%
Treatment protocol none Pat. N. %
Number of patients 20 23.5%
Causes:
Minor surgery 7 8.2%
Incomplete risk evaluation 11 12.9%
Refuse treatment 2 2.4%
ICF, Inferior vena cava filter; LMWH, low molecular weight heparin; Pat. N.,
patient number; TP, thromboprophylaxis.
Table 5 Thromboembolic events description
Location of PE Extension Pat. N.
Right lung Proximal 9 (10.6%)
Distal 20 (23.5%)
Proximal to distal 2 (2.4%)
Left lung Distal 7 (8.2%)
Bilateral Distal 14 (16.5%)
Proximal 21 (24.7%)
Proximal to distal 3 (3.5%)
Multifocal 4 (4.7%)
Proximal left and distal right 4 (4.7%)
Proximal right and distal left 1 (1.2%)
Total 85
Concomitant DVT: extension Pat. N
Proximal to the knee 11 (12.9%)
Distal to the knee 6 (7%)
Above and below the knee 11 (12.9%)
Total 28 (32.9%)
DVT, deep vein thrombosis; Pat. N., patient number; PE, pulmonary embolism.
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oral osteotomy with an Ilizarov frame), whereas the re-
maining 11 were managed non-operatively with plaster
of Paris and brace application (1 Achilles tendon rup-
ture, 4 ankle fractures, 1 ankle sprain, 4 metatarsal frac-
tures, 1 tibial plateau fracture).
Thromboembolic events
The overall incidence of PE was 0.46% (0.8% in the
trauma cohort and 0.18% in elective orthopedic inter-
ventions). The median time of PE diagnosis, from the
date of injury or the surgical intervention was 23 days
(range 1 to 312). Only one patient had a very late diag-
nosis of PE (after 312 days), because he had a DVT three
months after trauma to the left foot (fracture of the base
of the fifth metatarsal treated conservatively by cast im-
mobilization) and subsequently developed PE.
Out of the 85 patients forming the study cohort, there
were no recorded cases of hemodynamic instability. All
patients had a recorded systolic blood pressure of more
than 100 mmHg at the time of onset of the clinical symp-
toms suspicious for PE. Only two patients were found col-
lapsed with a respiratory problem, but the recorded vital
parameters were all stable except for respiratory rate. One
patient presented with an atypical presentation of gradual
worsening of shoulder tip pain for a week following a
muscle biopsy for a myositis and was confirmed to have
PE on CT-PA.
The most common signs and symptoms observed were
pleuritic chest pain, dyspnea, acute tachycardia and hyp-
oxia. Elevation of the D-dimer value was also commonly
observed. The mean simplified Pulmonary Embolism Se-
verity Index was 2.27 (SD = 1.14). The extension and
localization of the PE are shown in Table 5.
Concomitant DVT was present in 28 patients (32.9%)
with PE. Proximal DVT was observed in 11 patients,and in 6 patients distal DVT was observed. In the re-
maining 11 patients a DVT was identified both proximal
and distal to the knee joint (Table 5).
Hospitalization details
Within the study cohort the mean time for hospital stay
was 18.5 days (range 1 to 64 days). In 33 cases (39%), PE
developed during the in-hospital stay. In the remaining
cases, PE developed following hospital discharge necessi-
tating re-admission of these patients for treatment. The
mean length of stay (LOS) for PE re-admission was 8.5
days (range 1 to 28 days). In comparison to the same un-
complicated orthopedic surgical procedures, the onset of
PE led to an increase in the LOS, with a mean rise of
2.4-fold in hospitalization time.
Mortality
The overall inpatient mortality for the whole hospital co-
hort was 2.3% (419 out of 18,151 patients). Mortality
after PE was 0.07% (13 out of 18,151 patients) reaching
15.3% (13 out of 85) of the patients with a positive CT-PA
(Tables 1 and 2).
Out of the 13 patients who died, 7 underwent surgery
(5 proximal femur fracture and 2 for a vertebral meta-
static lesion) and 6 non-operative treatment (1 tibial pla-
teau, 2 metatarsal, 1 clavicle, 1 radial head and 1 ankle
fracture) (Tables 1 and 2).
For elective orthopedic procedures, the rate of morta-
lity was 0.02%, whereas in the trauma population it was
0.15%. Two patients (tibia plateau and metatarsal injury)
out of the 13 who died did not receive a TP treatment
Table 7 Regression coefficients expressed as ORs






Age per year 1.05 (1.01, 1.10) 1.06 (1.00, 1.12) 0.05
Charlson per
comorbidity
1.58 (1.20, 2.09) 2.02 (1.30, 3.16) 0.01
Prophylaxis
(other than aspirin)
0.29 (0.08, 1.05) 0.06 (0.01, 0.48) 0.01
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high-risk patients. These two patients were managed non-
operatively with a cast immobilization. Risk factors iden-
tified included previous history of DVT, malignancy,
congestive pulmonary disease and obesity.
Of the 13 patients who died, only 1 patient’s primary
cause of death was certified to be PE. The primary cau-
ses of death, as defined in the death certificate obtained
from the coroner for those who died in the hospital and
from the office of national statistics for those who died at
home, and certified by the doctor after discussion with the
coroner, are presented in Table 6.
In the trauma cohort the median time of death from
PE diagnosis was 36 days (range 5 to 151), whereas for the
elective orthopedic group it was 112 days (84 to 140).
The presence of two or more co-morbidities was sig-
nificantly associated with the incidence of mortality (un-
adjusted OR = 3.52, 95% CI (1.34, 18.99), P = 0.034).
Although there was also a similar clinical effect size for
polytrauma injury on mortality (unadjusted OR = 1.90
(0.38, 9.54), P = 0.218), evidence was not statistically sig-
nificant for this factor. We found little evidence of associ-
ation with gender, time of surgery, elective/trauma or the
proximal/distal position of embolism. For the following
factors, however, there was strong evidence (statistically
significant at the 5% level) expressed below as odds ratios
with 95% confidence intervals. Most importantly, there
was a strong associated risk of mortality following pul-
monary embolism in patients with high Charlson’s co-
morbidity index and the usage of thromboprophylaxis
was seen to be associated with a protective effect. Results
are given in Tables 7 and 8.
One more interesting observation we found in our
study was the association of mortality with age. FromTable 6 Causes of death
No Gender Age Cause of death
1 M 80 Lung cancer
2 M 64 Disseminated lung cancer
3 F 96 Bronchopneumonia
4 F 88 CCF, IHD*
5 M 90 CCF, IHD*
6 F 88 Spontaneous subdural hematoma
7 F 90 PE*, Bilateral DVT
8 F 63 Bronchopneumonia
9 M 60 Metastatic lung cancer
10 F 84 Aspiration pneumonia, stroke
11 F 79 Bronchopneumonia
12 M 64 Metastatic renal cancer
13 F 80 Pulmonary fibrosis
*; CCF, congestive cardiac failure; DVT, deep venous thrombosis; IHD, ischemic
heart disease; PE, pulmonary embolism.the 85 patients that developed PE following orthopedic
surgery, 11 died within six months. There was a statis-
tically significant trend recorded that found older pa-
tients more likely to die following a PE after orthopedic/
trauma admission.
Also, the presence of DVT was associated with in-
creased mortality following a PE after an orthopedic/
trauma admission. This association between DVT and
mortality was not statistically significant in this dataset.
Discussion
Despite continuous improvement in medical knowledge
and treatment modalities, the incidence of VTE and its
related complications has remained fairly static during
the last three decades [25]. Notwithstanding the imple-
mentation of prevention protocols, clinical manifestation
of PE is not clear or specific. PE may be expressed in a
silent way and can be missed by the clinical team. For
this reason, PE might be under diagnosed.
In our study population, the incidence of PE was in
line with data published in previous studies [1,9,12,
26-28]. On further subgroup analysis it was noted that
the incidence of PE was lower for the elective surgery
cohort (0.23%) compared to the data recently published
in the guidelines of the American College of Chest Phy-
sicians [26] (0.35%) and Markovic-Denic et al. [1] (1.6%),
but is comparable to that reported by Jean-Marie Janue







Number 74 11 85
Age, mean ± SD (yrs) 64.6 ± 17.9 77.7 ± 13.2 66.3 ± 17.8
Gender M/F 38/36 5/6 43/42
Charlson, median; IQR 1:2 3:5.5 1:3
Thromboprophylaxis Y/N 60/19 5/6 65/20
Time surgery or admission to
PE (days), median; IQR
18:30 23:29 19:30
Elective/Trauma 22/52 2/9 24/61
Proximal/Distal 33/36 4/4 37/40
PE, pulmonary embolism.
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et al. [29] who showed a rate of 0.27% in his study popula-
tion, which is lower than the rates reported by other stud-
ies [9,30]. These differences, nevertheless, are difficult to
explain in retrospective studies, performed in different
geographic areas with different protocols of prophylaxis
and treatment.
On the basis of current evidence, CT-PA is considered
the gold standard for the diagnosis of PE [13,31]. Chest
contrast enhanced CT replaced catheter angiography
due to its less invasive nature and accuracy, and has
been proven to be superior or equal to angiography [31].
The reported sensitivity for the diagnosis of PE with CT-
PA varies from 45 to 100% and the specificity from 78 to
100% [31]. CT-PA has some limitations in detecting iso-
lated sub-segmental PE [31], but the introduction of the
multi-detector CT technique currently allows evaluation
of pulmonary vessels down to the sixth order branches,
thus, significantly increasing the rate of detection of PE
(sensitivity: 83%, specificity: 96%) [14,32].
Many authors have attempted to correlate specific risk
factors to the development of PE. Strong correlation was
identified for the number and magnitude of surgical in-
terventions, previous history of VTE and the length of
the hospitalization period [25,33,34]. The next highly re-
ported risk factors for VTE are cardiovascular disease
[1,23,33,34] and obesity [10,12,23,35]. More than half of
our study cohort belongs to the high-risk category with
more than two risk factors being present as defined by
the NICE guidelines [16].
Although 79.3% of our study population was on TP
treatment, patients still developed PE. We could not iden-
tify any additional specific related factors to VTE develop-
ment, but we have observed that in our cohort, 62.4% of
patients were older than 60 years and 22.4% were more
than 80 years of age. Several studies reported age as an in-
dependent risk factor for VTE [1,26,36]. In our cohort,
many of these elderly patients also had lower limb path-
ology (83.5%). One may speculate a synergistic effect of
these two parameters in reducing mobility and leading to
a higher risk of developing PE. In a recent case-crossover
study reduced mobility was reported as a significant trig-
ger of hospitalization for VTE. The risk of VTE hospi-
talization was 4.2-fold greater in the time period when
reduced mobility occurred [37].
In 13 cases, TP treatment was not prescribed even
though the patients had risk factors for VTE. Eight of
these 13 cases sustained foot and ankle injuries, which
were managed non-operatively and followed up in the
outpatient fracture clinics. The reason for this can be
attributed to the lack of clarity of national and local
guidelines about TP treatment in the out-patient setting,
particularly with injury patterns that are considered as less
debilitating. Shibuya et al. [38] stated that routine use of TPtreatment in foot and ankle injuries is not warranted in
contrast to our findings, which support the view that even
minor foot injuries cannot be neglected and risk assessment
should be performed on an individual basis. This has led to
the expansion of the routine risk assessment of patients
treated in our out-patient setting and regular audit cycles
have been implemented to ensure consistent compliance.
Concomitant DVT was identified in one-third of our
study cohort. Knudson et al. [39] analyzed the American
College of Surgeons National Trauma Data Bank and
found 522 cases of PE out of 450,375 trauma patients
(0.11%). In only 16% of these cases a concomitant DVT
was diagnosed. In a prospective cohort study [40] of 397
patients with the clinical suspicion of PE, 149 were posi-
tive for PE and less than one-third had a concomitant
DVT. Cipolle et al. [41] performed a trauma registry
analysis of 10,141 trauma admissions, and found 30 ca-
ses of PE, of which only 5 (16.7%) had coexisting DVT.
Moreover, in a retrospective review of medical records
of 247 trauma patients who underwent TPA/CTV over a
three-year period, Velmahos et al. [42] recognized posi-
tive findings of PE in 46 patients (19%) and among these,
only 7 (15%) also had a DVT. Hypothesizing that CTPA/
CTV was considered the most accurate method for diag-
nosing VTE, the same authors [42] investigated this lack
of association between PE and DVT. They stated that it
was unlikely that a diagnosis of DVT could have been
significantly missed for an insufficient sensitivity of the
diagnostic tool. Therefore, they hypothesized that the
clots might be formed de novo within the pulmonary cir-
culation as a consequence of the changes within the lung
vascular endothelium and in the rheological blood prop-
erties induced by a post-traumatic hyper-adrenergic and
hyper-inflammatory state. However, there is still no de-
finitive evidence about the etiological relationship be-
tween DVT and PE, and further studies are desirable to
comprehend this phenomenon.
Our mortality was low and consistent with other re-
ports in the literature (Table 9). The low mortality rate
noted in the trauma patient subgroup could be attrib-
uted to the high percentage of less severe traumatic in-
juries (frequency of polytrauma patients: 11.9%) and to
the good compliance rate of implementing our TP treat-
ment protocols. Consequently, the average number of
co-morbidities in our sample was 2.6. A higher propor-
tion of non-survivors had three or more co-morbidities
in contrast to the survivors, and this difference was stat-
ically significant (P = 0.034).
The present study has several limitations, including
the retrospective nature of data collection, from the case
notes and electronic databases, the small sample size,
the short study period (two years) and the absence of a
control group. Moreover, our data pool documented
events occurring only during hospital stay (primary or
Table 9 Literature review on the incidence and mortality of PE
Elective
Author Year Type Incidence of PE Mortality




Falck-Ytter Y et al. [26] 2012 Guidelines THA: 0.3%
Markovic-Denic L et al. [1] 2012 Prospective THA: 1.6% 1.5%
TKA: 1.5%
Pedersen AB et al. [34] 2011 Retrospective TKA: 0.3%
Pedersen AB et al. [33] 2010 Retrospective THA: 0.3% 1% (0.05% PE rel)
*Poultsides LA et al. [11] 2012 Meta-analysis 0.38% (0.2 to 0.59)
Our study 0.2% 0.02%
Trauma
Author Year Type Incidence of PE Mortality
Jawa RS et al. [27] 2011 Retrospective 0.5%
Paffrath T et al. [9] 2010 Retrospective 0.9%
McNamara I et al. [30] 2009 Prospective 0.7%
Huseynova K et al. [28] 2009 Retrospective 0.7%
*Ho KM et al. [10] 2010 Retrospective 13.8% (1.6% PE rel)
Our study 0.8% 0.15%
*Study reporting PE-related mortality. PE, pulmonary embolism; THA, total hip arthroplasty; TKA, total knee arthroplasty.
The data have been compared with those of the current study.
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pulation could have been admitted or treated elsewhere
as we treat a number of tertiary referred patients and, as
such, we might have missed some patients who devel-
oped PE. Strengths of the study include the identification
of consecutive patients with specific injury patterns and
risk factors who sustained PE in a large teaching hospital
over a two-year period.
Conclusions
In this study, following the NICE guidelines for thrombo-
prophylaxis, the incidence of VTE was found to be similar
to the rates reported in the international literature, whereas
the mortality rate was considerably lower. It appears that
local protocols, in compliance with the NICE guidelines, are
effective in the prevention of VTE and in reducing mortality
in trauma and orthopedic patients. However, despite the
wide administration of both mechanical and chemical TP
treatment, patients can still develop PE. It appears that the
possibility of PE development is not only related to certain
patient related risk factors but also to the consequence of all
the aspects of the post-traumatic or post-surgical disease
process. Overall, the type of treatment, the type and length
of drug administration, the duration of immobilization and
the individual response of each patient appear to contribute
to the development of this rare yet fearful complication.Further studies are desirable to monitor the incidence
and outcome of PE in trauma and orthopedic patients so
that on-going vigilance and on-going evaluation of the
efficacy and effectiveness of treatment protocols will en-
sure that the morbidity will remain low and the mortal-
ity will continue to improve.
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